Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Next Previous
Trial Profile

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms POETYK Long-Term Extension; POETYK PSO-LTE
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 16 Feb 2025 According to a Bristol-Myers Squibb Media Release, new five-year result data were presented at the Winter Clinical Dermatology Conference Hawaii (WCH) in Big Island, Waikoloa Village, HI taking place February 14-19, 2025.
  • 16 Feb 2025 New five-year result presented in the Bristol-Myers Squibb Media Release.
  • 15 Jun 2024 Results of Maintenance of Response over 3 Years, presented at the 25th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top